RESUMEN
The paper reviews the publications dealing with Schnitzler syndrome, a rare autoinflammatory disease, and describes the authors' own clinical observation. It describes the first Russian experience in successfully using the interleukin-1 inhibitor canakinumab to treat this disease.
Asunto(s)
Anticuerpos Monoclonales/farmacología , Factores Inmunológicos/farmacología , Interleucina-1/antagonistas & inhibidores , Síndrome de Schnitzler/tratamiento farmacológico , Anticuerpos Monoclonales Humanizados , HumanosRESUMEN
Antisynthetase syndrome encompassing a symptom complex with severe interstitial lung disease is the severest subtype of polymyositis and dermatomyositis. The characteristic feature of antisynthetase syndrome is the insufficient efficiency of traditional therapy with glucocorticosteroids and cytostatics, which determines the prognosis of the disease and the need for new therapeutic approaches to treating these patients.
Asunto(s)
Anticuerpos Monoclonales de Origen Murino , Dermatomiositis/complicaciones , Miositis , Anticuerpos Monoclonales de Origen Murino/administración & dosificación , Anticuerpos Monoclonales de Origen Murino/efectos adversos , Anticuerpos Monoclonales de Origen Murino/inmunología , Antígenos CD20/análisis , Tratamiento Basado en Trasplante de Células y Tejidos/métodos , Dermatomiositis/inmunología , Monitoreo de Drogas , Humanos , Factores Inmunológicos/administración & dosificación , Factores Inmunológicos/efectos adversos , Factores Inmunológicos/inmunología , Enfermedades Pulmonares Intersticiales/etiología , Enfermedades Pulmonares Intersticiales/fisiopatología , Monitorización Inmunológica , Miositis/etiología , Miositis/inmunología , Miositis/fisiopatología , Miositis/terapia , Ensayos Clínicos Controlados Aleatorios como Asunto , Rituximab , Resultado del TratamientoRESUMEN
Clinical efficiency and safety of nimesil were studied in the multicenter open clinical trial of 52 patients with verified rheumatoid arthritis. Nimesil was given for 12 weeks in a daily dose 200-400 mg in addition to basic therapy. Clinical and laboratory parameters were assessed after 4 and 8 weeks of the treatment and after its end. The treatment produced a significant positive response of the articular syndrome. Marked improvement was registered in 11 (23.4%) patients, improvement--in 33 (79.2%) patients. Side effects were reversible and occurred in 8 (15.3%) patients. In 5 patients the drug was withdrawn. The conclusion is made on high efficiency and good tolerance of nimesil in rheumatoid arthritis patients.